Table 3 Reasons for anakinra withdrawal
From: Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey
Disease | No. withdrawals/treated patients | Inefficacy or loss of efficacy | Adverse event | Persistent remission | On-demand treatment | Patient request | Switch to canakinumab |
|---|---|---|---|---|---|---|---|
AOSD | 20/35 | 14 | 3 | 1 | 0 | 2 | 2 |
Gout | 18/28 | 0 | 0 | 17 | 1 | 0 | 0 |
SJIA | 16/26 | 7 | 3 | 5 | 0 | 1 | 6 |
CAPS | 11/21 | 1 | 1 | 1 | 0 | 8 | 3 |
MKD | 7/10 | 2 | 2 | 0 | 0 | 3 | 4 |
FMF | 6/13 | 1 | 3 | 0 | 1 | 1 | 3 |
SAPHO | 7/9 | 5 | 2 | 0 | 0 | 0 | 0 |
Schnitzler’s syndrome | 3/7 | 1 | 2 | 0 | 0 | 0 | 1 |
Spondylo arthritis | 5/5 | 2 | 3 | 0 | 0 | 0 | 0 |
Vasculitis | 2/4 | 2 | 0 | 0 | 0 | 0 | 2 |
Chondro calcinosis | 2/4 | 1 | 0 | 1 | 0 | 0 | 0 |
TRAPS | 1/3 | 1 | 0 | 0 | 0 | 0 | 0 |
GPP | 2/3 | 1 | 0 | 1 | 0 | 0 | 0 |
Polychondritis | 1/3 | 1 | 0 | 0 | 0 | 0 | 0 |
NAPS12 | 2/2 | 2 | 0 | 0 | 0 | 0 | 0 |